Effect of Haishengsu on transplanted K562 and drug-resistant K562/ADM tumors: An experimental study

Ji-Zhu Liu; Ming Yang; Da-Peng Li; Bin Zhang; Shou-Guo Chen; Chun-Bo Wang; Guang-Yao Li; Le-Xin Wang
April 2009
Clinical & Investigative Medicine;Apr2009, Vol. 32 Issue 2, pE117
Academic Journal
Purpose: To evaluate the effect of Haishengsu (HSS) on transplanted K562 and drug-resistant K562/ADM tumors. Methods: Mice were inoculated subcutaneously with K562 and K562/ADM cells, respectively. Tumour-bearing animals were divided into HSS, adriamycin, combination therapy (adriamycin plus HSS) and placebo groups. The anti-tumour effect was assessed by tumour growth curve and tumour inhibitory rate (IR). Results: In animals inoculated with K562 cells, the inhibitory rates of high (1800mg/kg) and medium (900mg/kg ) dose HSS groups were 100% and 96.4%, respectively, which was higher than that in the adriamycin (88.9%) or the combination therapy groups (85.8%, P<0.05). The inhibitory rate in the low-dose HSS group (53.4%) was lower than in all other groups (P<0.01). In mice inoculated with K562/ADM cells, the inhibitory rates in the high, medium and low dose HSS groups were 100%, 95.9%, and 44.1%, respectively. In the adriamycin group, the inhibitory rate was 23.07%, which was lower than in the HSS group (P < 0.01). Pathological examination of tumour tissues from HSS-treated animals showed extensive necrosis and bleeding. Conclusions: Haishengsu inhibits the growth of transplanted K562 tumours in mice. It is also effective in suppressing the growth of drug-resistant K562/ADM tumors in this animal model.


Related Articles

  • Sorafenib: In Hepatocellular Carcinoma. Simpson, Dene; Keating, Gillian M. // Drugs;2008, Vol. 68 Issue 2, p251 

    Sorafenib is an orally active multikinase inhibitor with anti-tumour activity. It was recently approved in the US and the EU for the treatment of patients with hepatocellular carcinoma. Oral sorafenib 400 mg twice daily significantly improved survival in patients with advanced hepatocellular...

  • European Society for Medical Oncology.  // BioWorld Today;10/2/2012, Vol. 23 Issue 191, p9 

    The article reports on the positive results obtained by CytRx Corp. from a Phase Ib/II trial of its tumor-targeting doxorubicin conjugate aldoxorubicin in patients with advanced soft-tissue sarcoma.

  • Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Bonate, Peter; Suttle, A. // Cancer Chemotherapy & Pharmacology;Jul2013, Vol. 72 Issue 1, p231 

    Purpose: The purpose of this study is to characterize tumor growth kinetics in patients with renal cell carcinoma (RCC) after treatment with pazopanib or placebo and to identify predictive patient-specific covariates. Methods: Different tumor growth models that included patient-specific...

  • Prohibit Placebo Controls? Ganter, Jane // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p10 

    Comments on the use of placebo control in clinical trials for the treatment of life threatening disorders. Debate over the ethical issues of placebos; Application of the double standard thinking in placebos; Impact of the zero risk and tolerance demand on the debate resolution.

  • Case study: The placebo effect.  // Patient Care;9/15/2001, Vol. 35 Issue 17, p40 

    Provides information on a study which examined clinical trials comparing the treatment with placebo effect. Reliability of the clinical trials; Validity of the findings.

  • In Clinical Trials and In the Clinic, What Is the Placebo's Effect? Wang, Linda // JNCI: Journal of the National Cancer Institute;Jan2003, Vol. 95 Issue 1, p6 

    Reports on issues regarding the use of placebos in clinical trials. Relevant research on the placebo effect; Importance of placebo control in prevention studies; Use of placebo outside of clinical trials.

  • Lessons Learned from Attempts To Establish the Blind in Placebo-Controlled Trials of Zinc for the Common Cold. Desbiens, Norman A. // Annals of Internal Medicine;8/15/2000, Vol. 133 Issue 4, p302 

    Editorial. Discusses the use of placebo-controlled trials in determining the effectiveness of zinc in treating common colds. Prevalent use of double-blind, placebo-controlled trials; Problems with placebo clinical trials; Ability of patients to determine the presence of placebo in the trials;...

  • CNE/CME questions.  // IRB Advisor;Sep2009, Vol. 9 Issue 9, p108 

    A quiz related to clinical trials and placebo is presented.

  • Placebo threatened with extinction.  // British Columbia Medical Journal;Jun2011, Vol. 53 Issue 5, p236 

    The article focuses on the skepticism of the medical community concerning the use of placebos and the concerns raised on the scientific integrity of the randomized clinical trials (RCT).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics